The International Myeloma Foundation (IMF) Honors 2022 Research Achievement Awardees, Dr. Hervé Avet-Loiseau and Dr. Bruno Paiva Read more about The International Myeloma Foundation (IMF) Honors 2022 Research Achievement Awardees, Dr. Hervé Avet-Loiseau and Dr. Bruno PaivaAdd new comment
International Myeloma Foundation Welcomes Fatima Scipione as Senior Vice President of Strategic Alliances and External Affairs Read more about International Myeloma Foundation Welcomes Fatima Scipione as Senior Vice President of Strategic Alliances and External Affairs Add new comment
IMF Names Recipients of 2022 Brian D. Novis Research Grants Read more about IMF Names Recipients of 2022 Brian D. Novis Research GrantsAdd new comment
Join the Fight Against Myeloma by Supporting the IMF’s Novel Research Read more about Join the Fight Against Myeloma by Supporting the IMF’s Novel Research Add new comment
IMF Asian Myeloma Network (AMN) Holds Groundbreaking Events in 2021 Read more about IMF Asian Myeloma Network (AMN) Holds Groundbreaking Events in 2021 Add new comment
Cancer Drug Parity Act Update—Patients Must Have Access to Oral Cancer Therapies Read more about Cancer Drug Parity Act Update—Patients Must Have Access to Oral Cancer TherapiesAdd new comment
With Over 30 Million Reached Across 46 Countries, the International Myeloma Foundation (IMF) Makes a Global Impact for 2022 Myeloma Action Month Read more about With Over 30 Million Reached Across 46 Countries, the International Myeloma Foundation (IMF) Makes a Global Impact for 2022 Myeloma Action Month Add new comment
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Read more about U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaAdd new comment
International Myeloma Foundation (IMF) Launches MYeloma ACTION Campaign for Myeloma Action Month in March 2022 Read more about International Myeloma Foundation (IMF) Launches MYeloma ACTION Campaign for Myeloma Action Month in March 2022Add new comment
Janssen Submits Biologics License Application to FDA Seeking Approval of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Patients Read more about Janssen Submits Biologics License Application to FDA Seeking Approval of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Patients Add new comment
